Icosavax push­es for­ward com­bo RSV-hM­PV vac­cine and an­nounces di­rect stock of­fer­ing

Seat­tle-based Icosavax may have failed in its at­tempt at a Covid-19 vac­cine in 2022, but it re­leased ear­ly da­ta on its bi­va­lent vac­cine can­di­date for RSV and hu­man metap­neu­movirus (hM­PV) — and an­nounced a $67.8 mil­lion di­rect of­fer­ing of its com­mon stock yes­ter­day.

The vac­cine can­di­date for old­er adults, dubbed IVX-A12 and grant­ed fast track des­ig­na­tion by the FDA, is made up of the com­pa­ny’s RSV and hM­PV vac­cines. The bi­va­lent vac­cine could po­ten­tial­ly take mean­ing­ful mar­ket share in a fu­ture ~$10 bil­lion+ mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER